Madrigal Pharmaceuticals, Inc., planned to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on January 31, 2022. Madrigal's lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-ß selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
275.4 USD | -1.67% |
|
-0.24% | +19.01% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.01% | 586.83Cr | |
+16.49% | 12TCr | |
+21.73% | 12TCr | |
+22.18% | 2.66TCr | |
-21.81% | 1.99TCr | |
-16.89% | 1.63TCr | |
-18.81% | 1.55TCr | |
-44.74% | 1.55TCr | |
+62.72% | 1.48TCr | |
+3.09% | 1.37TCr |
- Stock Market
- Equities
- MDGL Stock
- News Madrigal Pharmaceuticals, Inc.
- Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom